Literature DB >> 21468743

Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM).

Selma B Souto1, Eliana B Souto, Daniel C Braga, José L Medina.   

Abstract

The urgent need to treat type 2 diabetes mellitus (T2DM), which is currently reaching epidemic proportions, has been a major focus of healthcare systems and policy makers worldwide. Pharmacological treatment and lifestyle interventions together with the control of cardiovascular risk factors are the main strategies to prevent or delay the onset of T2DM. The present review discusses the state of the art knowledge of effective therapeutic approaches (metformin, thiazolidinediones, nateglinides, α-glucosidase inhibitors, incretin-based and angiotensin-based therapies, weight reducers, statins, fibric acid derivatives), including surgery, and identifies the major lifestyle changes for specific target groups.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21468743     DOI： 10.1007/s00228-011-1038-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  64 in total

Review 1.  The prevention or delay of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

2.  Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.

Authors:  A Rovellini; D Sommariva; A Branchi; F Maraffi; C Montalto; R Gandini; A Fasoli
Journal:  Pharmacol Res       Date:  1992-04       Impact factor: 7.658

3.  Is type II diabetes mellitus (NIDDM) a surgical disease?

Authors:  W J Pories; K G MacDonald; E G Flickinger; G L Dohm; M K Sinha; H A Barakat; H J May; P Khazanie; M S Swanson; E Morgan
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

4.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

5.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Authors:  Jaana Lindström; Pirjo Ilanne-Parikka; Markku Peltonen; Sirkka Aunola; Johan G Eriksson; Katri Hemiö; Helena Hämäläinen; Pirjo Härkönen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Paturi; Jouko Sundvall; Timo T Valle; Matti Uusitupa; Jaakko Tuomilehto
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 7.  Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.

Authors:  Manfredi Rizzo; Ali A Rizvi; Giatgen A Spinas; Giovam Battista Rini; Kaspar Berneis
Journal:  Expert Opin Investig Drugs       Date:  2009-10       Impact factor: 6.206

8.  Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Authors:  Robert M Califf; Mitradev Boolell; Steven M Haffner; M Angelyn Bethel; John McMurray; Anil Duggal; Rury R Holman
Journal:  Am Heart J       Date:  2008-10       Impact factor: 4.749

9.  Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

Authors:  Alexander Tenenbaum; Michael Motro; Enrique Z Fisman; Ehud Schwammenthal; Yehuda Adler; Ilan Goldenberg; Jonathan Leor; Valentina Boyko; Lori Mandelzweig; Solomon Behar
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

10.  Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study.

Authors:  S D Long; K O'Brien; K G MacDonald; N Leggett-Frazier; M S Swanson; W J Pories; J F Caro
Journal:  Diabetes Care       Date:  1994-05       Impact factor: 19.112
View more
  9 in total

1.  Effect of zinc supplementation on type 2 diabetes parameters and liver metallothionein expressions in Wistar rats.

Authors:  Xue Wang; Hongyan Li; Zhe Fan; Ya Liu
Journal:  J Physiol Biochem       Date:  2012-05-15       Impact factor: 4.158

2.  Incidence and risk factors of type 2 diabetes mellitus in an overweight and obese population: a long-term retrospective cohort study from a Gulf state.

Authors:  Dybesh Regmi; Saif Al-Shamsi; Romona D Govender; Juma Al Kaabi
Journal:  BMJ Open       Date:  2020-07-02       Impact factor: 2.692

3.  Short and long-term effects of Baccharis articulata on glucose homeostasis.

Authors:  Virginia D Kappel; Danielle F Pereira; Luisa H Cazarolli; Samantha M Guesser; Carlos H Blum da Silva; Eloir P Schenkel; Flávio H Reginatto; Fátima R M B Silva
Journal:  Molecules       Date:  2012-06-04       Impact factor: 4.411

4.  Efficacy and adverse reaction to different doses of atorvastatin in the treatment of type II diabetes mellitus.

Authors:  Hua Jiang; Hong Zheng
Journal:  Biosci Rep       Date:  2019-07-05       Impact factor: 3.840

Review 5.  Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II.

Authors:  Raquel Vieira; Selma B Souto; Elena Sánchez-López; Ana López Machado; Patricia Severino; Sajan Jose; Antonello Santini; Amelia M Silva; Ana Fortuna; Maria Luisa García; Eliana B Souto
Journal:  J Clin Med       Date:  2019-08-28       Impact factor: 4.241

Review 6.  Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I.

Authors:  Raquel Vieira; Selma B Souto; Elena Sánchez-López; Ana López Machado; Patricia Severino; Sajan Jose; Antonello Santini; Ana Fortuna; Maria Luisa García; Amelia M Silva; Eliana B Souto
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-10

Review 7.  Biomedical Potential of Plant-Based Selenium Nanoparticles: A Comprehensive Review on Therapeutic and Mechanistic Aspects.

Authors:  Muhammad Ikram; Bilal Javed; Naveed Iqbal Raja; Zia-Ur-Rehman Mashwani
Journal:  Int J Nanomedicine       Date:  2021-01-12

8.  Sucupira Oil-Loaded Nanostructured Lipid Carriers (NLC): Lipid Screening, Factorial Design, Release Profile, and Cytotoxicity.

Authors:  Raquel Vieira; Patricia Severino; Luciana A Nalone; Selma B Souto; Amélia M Silva; Massimo Lucarini; Alessandra Durazzo; Antonello Santini; Eliana B Souto
Journal:  Molecules       Date:  2020-02-06       Impact factor: 4.411

Review 9.  Nanoparticle Delivery Systems in the Treatment of Diabetes Complications.

Authors:  Eliana B Souto; Selma B Souto; Joana R Campos; Patricia Severino; Tatiana N Pashirova; Lucia Y Zakharova; Amélia M Silva; Alessandra Durazzo; Massimo Lucarini; Angelo A Izzo; Antonello Santini
Journal:  Molecules       Date:  2019-11-20       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.